Jpmorgan Chase & CO Nurix Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 68,148 shares of NRIX stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,148
Previous 36,796
85.2%
Holding current value
$1.33 Million
Previous $767,000
99.35%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
68.1MCall Options Held
78KPut Options Held
53.8K-
Black Rock Inc. New York, NY6.82MShares$133 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$83.8 Million6.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$78.5 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$76 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$75.7 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $923M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...